Evidence map›Paper›PMID 35752869›Full record

ArticleBMC research notes2022

Utility of CD138/syndecan-1 immunohistochemistry for localization of plasmacytes is tissue-dependent in B6 mice.

David K Meyerholz, Mariah R Leidinger, J Adam Goeken, Thomas R Businga, Allison Akers, Sebastian Vizuett, Courtney A Kaemmer, Jordan L Kohlmeyer, Rebecca D Dodd, Dawn E Quelle

Open access · goldAbstract read
In one paragraph

Article in BMC research notes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  5. Preclinical Evaluation of aPharmaceutics · 2023
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

David K MeyerholzDepartment of Pathology, University of Iowa, Iowa City, IA, USA. david-meyerholz@uiowa.edu.ORCID http://orcid.org/0000-0003-1552-3253
Mariah R LeidingerDepartment of Pathology, University of Iowa, Iowa City, IA, USA.
J Adam GoekenDepartment of Pathology, University of Iowa, Iowa City, IA, USA.
Thomas R BusingaDepartment of Pathology, University of Iowa, Iowa City, IA, USA.
Allison AkersDepartment of Pathology, University of Iowa, Iowa City, IA, USA.
Sebastian VizuettDepartment of Pathology, University of Iowa, Iowa City, IA, USA.
Courtney A KaemmerDepartment of Neuroscience and Pharmacology, University of Iowa, Iowa City, IA, USA.
Jordan L KohlmeyerDepartment of Pathology, University of Iowa, Iowa City, IA, USA.
Rebecca D DoddDepartment of Internal Medicine, University of Iowa, Iowa City, IA, USA.
Dawn E QuelleDepartment of Pathology, University of Iowa, Iowa City, IA, USA.
University of Iowa · US

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Jon C.D. Houtman · 2000 to 2026
$70.0M
Respiratory virus infection in early cystic fibrosis lung diseaseP01HL091842 · NHLBI · UNIVERSITY OF IOWA · PI ZABNER, JOSEPH · 2008 to 2022
$34.2M
Vector Core-Core 2P30DK054759 · NIDDK · UNIVERSITY OF IOWA · PI Alejandro Antonio Pezzulo · 1998 to 2026
$30.5M
Project 4: New Approaches to Improving the Effectiveness of Radionuclide Targeted Treatments in Neuroendocrine TumorsP50CA174521 · NCI · UNIVERSITY OF IOWA · PI MENDA, YUSUF · 2015 to 2021
$13.2M
Pathology CoreP01HL152960 · NHLBI · UNIVERSITY OF IOWA · PI ENGELHARDT, JOHN F · 2020 to 2024
$11.6M
NHLBI NIH HHS P01 HL091842NHLBI NIH HHS P01 HL152960NIH HHS CA086862NIH HHS CA174521NIH HHS DK054759NIH HHS HL091842NIH HHS HL152960
6 · The paper itself

Abstract

objectiveInflammation is present in many diseases and identification of immune cell infiltration is a common assessment. CD138 (syndecan-1) is a recommended immunohistochemical marker for human plasmacytes although it is also expressed in various epithelia and tumors. Similarly, CD138 is a marker for murine plasmacytes, but its tissue immunostaining is not well-defined. Endogenous CD138 expression is an important confounding factor when evaluating plasmacyte infiltration. We studied two plasmacyte markers (CD138 and Kappa light chains) for endogenous immunostaining in five organs and one tumor from B6 mice.

resultsPlasmacytes in Peyer's patches were positive for CD138 and Kappa markers without endogenous immunostaining. Endogenous CD138 immunostaining was widespread in liver, kidney, lung and a malignant peripheral nerve sheath tumor (MPNST) versus regionalized immunostaining in skin and small intestine wall. Endogenous Kappa immunostaining was absent in all tissues except for plasmacytes. Tissues with widespread endogenous CD138 immunostaining were contrasted by absence of endogenous Kappa immunostaining. Here, plasmacytes would not be distinguished by CD138, but would be obvious by Kappa immunostaining. Our study suggests that utility of immunostaining for plasmacytes by CD138 is tissue dependent in mice. Additionally, Kappa immunostaining may be a useful alternative in mouse tissues with confounding endogenous CD138 immunostaining.

Indexed as

NeoplasmsSyndecan-1AnimalsBiomarkersImmunohistochemistryMicePlasma CellsBiomarkersSyndecan-1B-cellsCD138/syndecan-1ImmunohistochemistryKappa light chainPlasmacytes

Identifiers

PMID35752869
PMCPMC9233769
OpenAlexW4283446047

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.